WELCOME TO The Biotechnology REPORT
Institute of Genetics and Animal Breeding of the Polish Academy of Sciences
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cantargia AB | July 05, 2022
Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows
Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital.
Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDA...
Synaffix | September 07, 2022
Synaffix B.V. and Emergence Therapeutics AG announce that the Companies have entered into a licensing agreement of up to $360 million, providing Emergence access on a target-specific basis to Synaffix's proprietary antibody drug conjugate technologies comprising GlycoConnect™, HydraSpace™ and SYNtecan E™ linker-payload.
Under the terms of the agreement, Synaffix will be eligible to receive up to $360 million in upfront and milestone payments plus royalties on...
Industrial Impact, Medical
Businesswire | March 29, 2023
Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has entered into a strategic collaboration agreement with Novartis to develop, manufacture and commercialize Bicycle® radio-conjugates (BRCs) for multiple agreed upon oncology targets.
“This collaboration builds on the groundbreaking clinical work we have been doing in the...
Angel Yeast | July 27, 2022
Angel Yeast a globally listed yeast and yeast extract manufacturer, has inked an agreement with Bejing PhaBuilder Biotechnology Co., Ltd in Yichang, Hubei province to build a large manufacturing base for polyhydroxyalkanoates (PHA) in the city. The pair will set up a joint venture company to drive the application of synthetic biology in the biotechnology industry.
PHA is a polyester produced naturally by microorganisms. The biodegradable and biocompatible properties of PHA make it...
Cell and Gene Therapy
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE